Inflammation in peritoneal Dialysis: A Latin-American perspective

Peritoneal Dialysis International

Volumn 27, Issue 3, 2007, Pages 347-352

  Cueto Manzano, Alfonso M ^a   González Espinoza, Liliana ^a   del Campo, Fabiola Martin ^a   Fortes, Paulo C ^b   Pecoits Filho, Roberto ^b  

^a HOSPITAL DE ESPECIALIDADES   (Mexico)

^b PONTIFICAL CATHOLIC UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

Cardiovascular risk; Inflammation; Latin America

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; C REACTIVE PROTEIN; DIALYSIS FLUID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; PRAVASTATIN;

AGE; ATHEROSCLEROSIS; BACTERIAL INFECTION; CANCER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DIABETES MELLITUS; DIALYSATE; ENVIRONMENTAL FACTOR; HEREDITY; HUMAN; HYPOALBUMINEMIA; INFLAMMATION; LIFESTYLE; MALNUTRITION; MORTALITY; OXIDATIVE STRESS; PERITONEAL DIALYSIS; PERITONITIS; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SOUTH AND CENTRAL AMERICA; UREMIA;

EID: 34447318060     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080702700326     Document Type: Review

References (49)

1. Li PK, Chow KM. The clinical and epidemiological aspects of vascular mortality in chronic peritoneal dialysis patients. Perit Dial Int 2005; 25(Suppl 3):S80-3.
2. World Bank. The World Bank Group. Available at: http://www.worldbank.org [Accessed 1 November 2006.]
3. Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest 1997; 100:2153-7.
4. Libby P, Sukhova G, Lee RT, Galis ZS. Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. J Cardiovasc Pharmacol 1995; 25(Suppl 2): S9-12.
5. Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998; 351(9096): 88-92.
6. Stenvinkel P, Lindholm B, Heimburger M, Heimburger O. Elevated serum levels of soluble adhesion molecules predict death in pre-dialysis patients: association with malnutrition, inflammation, and cardiovascular disease. Nephrol Dial Transplant 2000; 15:1624-30.
7. Bergström J, Heimburger O, Lindholm B, Qureshi AR. Elevated serum C-reactive protein is a strong predictor of increased mortality and low serum albumin in hemodialysis (HD) patients [Abstract]. J Am Soc Nephrol 1995; 6:573.
8. Ducloux D, Bresson-Vautrin C, Kribs M, Abdelfatah A, Chalopin JM. C-reactive protein and cardiovascular disease in peritoneal dialysis patients. Kidney Int 2002; 62: 1417-22.
9. Noh H, Lee SW, Kang SW, Shin SK, Choi KH, Lee HY, et al. Serum C-reactive protein: a predictor of mortality in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1998; 18:387-94.
10. Wang AY, Woo J, Lam CW, Wang M, Sea MM, Lui SF, et al. Is a single time point C-reactive protein predictive of outcome in peritoneal dialysis patients? J Am Soc Nephrol 2003; 14:1871-9.
11. Witowski J, Jorres A, Coles GA, Williams JD, Topley N. Superinduction of IL-6 synthesis in human peritoneal mesothelial cells is related to the induction and stabilization of IL-6 mRNA. Kidney Int 1996; 50:1212-23.
12. Serre AF, Marie C, Beaujon G, Betail G, Cavaillon JM, Deteix P. Variations of cytokine levels and production in CAPD patients. Int J Artif Organs 1997; 20:614-21.
13. Pecoits-Filho R, Stenvinkel P, Heimburge O, Lindholm B. Beyond the membrane - the role of new PD solutions in enhancing global biocompatibility. Kidney lnt Suppl 2003; 88:S124-32.
14. Chung SH, Heimburger O, Stenvinkel P, Wang T, Lindholm B. Influence of peritoneal transport rate, inflammation, and fluid removal on nutritional status and clinical outcome in prevalent peritoneal dialysis patients. Perit Dial Int 2003; 23:174-83.
15. Stenvinkel R, Ketteler M, Johnson RJ, Lindholm B, Pecoits-Filho R, Riella M, et al. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia - the good, the bad, and the ugly. Kidney Int 2005; 67:1216-33.
16. Pecoits-Filho R, Nordfors L, Lindholm B, Hoff CM, Schalling M, Stenvinkel P. Genetic approaches in the clinical investigation of complex disorders: malnutrition, inflammation, and atherosclerosis (MIA) as a prototype. Kidney Int Suppl 2003; 84:S162-7.
17. Cueto-Manzano AM, Rojas-Campos E, Martinez-Ramirez HR, Valera-Gonzalez I, Medina M, Monteon F, et al. Can the inflammation markers of patients with high peritoneal permeability on continuous ambulatory peritoneal dialysis be reduced on nocturnal intermittent peritoneal dialysis? Perit Dial Int 2006; 26:341-8.
18. Avila-Diaz M, Ventura MD, Valle D, Vicente-Martinez M, Garcia-Gonzalez Z, Cisneros A, et al. Inflammation and extracellular volume expansion are related to sodium and water removal in patients on peritoneal dialysis. Perit Dial Int 2006; 26:574-80.
19. Paniagua R, de Jesús Ventura M, Rodriguez E, Sil J, Galindo T, Hurtado ME, et al. Impact of fill volume on peritoneal clearances and cytokine appearance in peritoneal dialysis. Perit Dial Int 2004; 24:156-62.
20. Sabath E, Vega O, Correa-Rotter R. Referencia temprana al nefrólogo: impacto sobre la hospitalización inicialy los seis primeros meses en diálisis peritoneal continua ambutatoria. Rev Invest Clin 2003; 55:489-93.
21. Cueto-Manzano AM, Quintana-Pina E, Correa-Rotter R. Long-term CAPD survival, and analysis of mortality risk factors: 12-year experience of a single Mexican center. Perit Dial Int 2001; 21:148-53.
22. Garcia G, Briseno G, Luquin H, Ibarra M, Cueto A. Timing of dialysis initiation and patient survival among disadvantaged populations in Mexico [Abstract]. J Am Soc Nephrol 2004; 15: 390A.
23. Cueto-Manzano AM, Correa-Rotter R. Is high peritoneal transport rate an independent risk factor for CAPD mortality? Kidney Int 2000; 57:314-20.
24. Saade M, Joglar F. Chronic peritoneal dialysis: seven-year experience in a large Hispanic program. Perit Dial Int 1995; 15:37-41.
25. Gamba G, Mejia JL, Saldivar S, Pena JC, Correa-Rotter R. Death risk in CAPD patients. The predictive value of the initial clinical and laboratory variables. Nephron 1993; 65: 23-7.
26. Su-Hernandez L, Abascal-Macias A, Mendez-Bueno FJ, Paniagua R, Amato D. Epidemiologic and demographic aspects of peritoneal dialysis in Mexico. Perit Dial Int 1996; 16:362-5.
27. Paniagua R, Amato D, Vonesh E, Correa-Rotter R, Ramos A, Moran J, et al. Effects of increased peritoneal. clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 2002; 13:1307-20.
28. Paniagua R, Frias Y, de Jesús Ventura M, Rodriguez E, Hurtado ME, Atcantara G, et al. C-reactive protein and anti-Chlamydia pneumoniae antibodies as risk factors of cardiovascular death in incident patients on peritoneal dialysis. Perit Dial Int 2003; 23:132-7.
29. Maiorca R, Vonesh EF, Cavalli P, De Vecchi A, Giangrande A, La Greca G, et al. A multicenter, selection-adjusted comparison of patient and technique survivals on CAPD and hemodialysis. Perit Dial Int 1991; 11:118-27.
30. Avram MM, Mittman N, Bonomini L, Chattopadhyay J, Fein P. Markers for survival in dialysis: a seven-year prospective study. Am J Kidney Dis 1995; 26:209-19.
31. Johnson JG, Gore SM, Firth J. The effect of age, diabetes, and other comorbidity on the survival of patients on dialysis: a systematic quantitative overview of the literature. Nephrol Dial Transplant 1999; 14:2156-64.
32. Churchill DN, Thorpe KE, Nolph KD, Keshaviah PR, Oreopoulos DG, Page D. Increased peritoneal membrane transport is associated with decreased patient and technique survival for continuous peritoneal dialysis patients. The Canada-USA (CANUSA) Peritoneal Dialysis Study Group. J Am Soc Nephrol 1998; 9:1285-92.
33. Brimble KS, Walker M, Margetts PJ, Kundhal KK, Rabbat CG. Meta-anatysis: peritoneal, membrane transport, mortality, and technique failure in peritoneal dialysis. J Am Soc Nephrol 2006; 17:2591-8.
34. Diaz-Alvarenga A, Abasta-Jimenez M, Bravo B, Gamba G, Correa-Rotter R. Serum albumin and body surface area are the strongest predictors of the peritoneal transport type. Adv Petit Dial 1994; 10:47-51.
35. Cueto-Manzano AM, Gamba G, Correa-Rotter R. Peritoneal protein loss in patients with high peritoneal. permeability: comparison between continuous ambulatory peritoneal dialysis and daytime intermittent peritoneal dialysis. Arch Med Res 2001; 3 2:197-201.
36. Cueto-Manzano AM, Espinosa A, Hernandez A, Correa-Rotter R. Peritoneal transport kinetics correlate with serum albumin but notwith the overall nutritional status in CAPD patients. Am J Kidney Dis 1997; 30:229-36.
37. Pecoits-Filho R, Araujo MR, Lindholm B, Stenvinkel. P, Abensur H, Romao JE Jr, et al. Plasma and dialysate IL-6 and VEGF concentrations areassociated with high peritoneal. solute transport rate. Nephrol Dial Transplant 2002; 17:1480-6.
38. Cueto-Manzano AM, Salazar M, Valera-Gonzalez I, Rojas-Campos E, Martinez-Ramirez HR, Cortes-Sanabria L, et al. Association between the peritoneal. transport rate and systemic inflammation marker in continuous ambulatory peritoneal dialysis (CAPD) [Abstract]. J Am Soc Nephrol 2002; 13:201A.
39. Pecoits-Filho R, Carvalho MJ, Stenvinket P, Lindholm B, Heimburger O. Systemic and intraperitoneal interleukin-6 system during the first year of peritoneal dialysis. Perit Dial Int 2006; 26:53-63.
40. Pecoits-Filho R, Barany P, Lindholm B, Heimburger 0, Stenvinkel P. Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant 2002; 17:1684-8.
41. Angel JR, Rojas-Campos E, Martín-del-Campo F, Camacho R, Nava D, Cueto-Manzano AM. Prevalencia del fenópmeno inflamatorio en pacientes en DPCA de 5 hospitales del estado de Jalisco [Abstract]. Resúmenes de la LIV Reunión Anual del Instituto Mexicano de Investigaciones Nefrológicas, November 30 - December 3, 2005, Puerto Vallarta, Jalisco, Mexico. 2005: 182.
42. Pecoits-Filho R, Lindholm B, Stenvinkel P. The malnutrition, inflammation, and atherosclerosis (MIA) syndrome the heart of the matter. Nephrol Dial Transplant 2002; 17(Suppl 11):28-31.
43. Reddy KS, Yusuf S. Emerging epidemic of cardiovascular disease in developing countries. Circulation 1998; 97: 596-601.
44. Leinonen M, Saikku P. Evidence for infectious agents in cardiovascular disease and atherosclerosis. Lancet Infect Dis 2002; 2(1):11-17.
45. Farsak B, Yildirir A, Akyon Y, Pinar A, Oc M, Boke E, et al. Detection of Chlamydia pneumoniae and Helicobacter pylori DNA in human atherosclerotic plaques by PCR. J Clin Microbial 2000; 38:4408-11.
46. Campbell DI, Warren BF, Thomas JE, Figura N, Telford JL, Sullivan PB. The African enigma: low prevalence of gastric atrophy, high prevalence of chronic inflammation in West African adults and children. Helicobacter 2001; 6:263-7.
47. Aguilera A, Codoceo R, Bajo MA, Diez JJ, del. Peso G, Pavone M, et al. Helicobacter pytori infection: a new cause of anorexia in peritoneal dialysis patients. Perit Dial Int 2001; 21(Suppl 3):S152-6.
48. Vernaglione L, Cristofano C, Muscogiuri P, Chimienti S. Does atorvastatin influence serum C-reactive protein levels in patients on long-term hemodialysis? Am J Kidney Dis 2004; 43:471-8.
49. Libetta C, Rampino T, Dal Canton A. Polarization of T-helper lymphocytes toward the Th2 phenotype in uremic patients. Am J Kidney Dis 2001; 38:286-95.